how to maintain semaglutide weight loss for Oral GLP-1 Medication Helps Patients

**: RVH not established

Information provided is for educational reference and does not constitute medical advice.

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for two primary indications: type 2 diabetes mellitus (marketed as Mounjaro) and chronic weight management (marketed as Zepbound)

doi: 10.1016/S1474-4422(23)00378-2

A body-composition scan cannot answer that by itself

With obesity affecting around 15 million people in the UK, the new dose is expected to provide healthcare professionals with more options to tailor treatments for patients